Single Source contract with Cardinal Health 105

Stony Brook University Hospital has secured a single-source exemption from advertising in the New York State Contract Reporter for the procurement of Kite Pharma's CAR-T therapy products, specifically axicabtagene ciloleucel and Tecartus™ (brexucabtagene autoleucel). This exemption was granted by the Office of the State Comptroller due to Cardinal Health 105 being the designated sole-source award recipient, enabling the hospital to directly purchase these biological cancer treatments without a competitive bidding process. The contract, which spans two years until October 21, 2025, covers all counties in New York State and involves a contract value estimated between 5 million and 20 million dollars. The partnership with Cardinal Health 105 facilitates order-to-cash services for these specialized therapies, which are used for refractory mantle cell lymphoma and other indications. The procurement process was initiated under solicitation number 2127660, with the primary point of contact being Roshni Rahman, Contract Officer III, reachable via email or phone. The contract's purpose is to ensure the hospital's access to these advanced immunotherapy treatments, which are critical for certain cancer patients. As this is a sole-source arrangement, questions or comments regarding the exemption or procurement process are directed to the designated contact at the contracting agency. The notice emphasizes the exclusive nature of this procurement due to the product's single-source status, streamlining access to these specialized therapies across all New York State counties.